Drug toxicity

药物毒性
  • 文章类型: Letter
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    从2019年到2020年,在美国所有药物过量死亡的15%中发现了抗组胺药,经常与芬太尼共同给药,3.6%的过量死亡是由于单独的抗组胺药。在所有这些报告的死亡中发现的最常见的抗组胺药是苯海拉明,一个无处不在的,非处方药和临床重要药物。目前,苯海拉明过量没有解毒剂.这篇综述总结了苯海拉明的不良健康影响和当前的急诊医学治疗方法。回顾了几例急诊医学病例报告,并比较了各种治疗方法的疗效和结果。审查的治疗方法包括更传统的抗组胺药过量治疗毒扁豆碱和碳酸氢钠,以及较新的如多奈哌齐,右美托咪定,和脂肪乳剂治疗。我们得出的结论是,需要更多的研究来确定治疗抗组胺药过量的理想治疗方法。
    From 2019 to 2020, antihistamines were found in 15% of all US drug overdose deaths, often co-administered with fentanyl, with 3.6% of overdose deaths due to antihistamines alone. The most common antihistamine found in all these reported deaths is diphenhydramine, a ubiquitous, over-the-counter and clinically important medication. Currently, there is no antidote for diphenhydramine overdose. This review summarizes the adverse health effects and current emergency medicine treatments for diphenhydramine. Several emergency medicine case reports are reviewed, and the efficacy and outcomes of a variety of treatments are compared. The treatments reviewed include the more traditional antihistamine overdose therapeutics physostigmine and sodium bicarbonate, as well as newer ones such as donepezil, dexmedetomidine, and lipid emulsion therapy. We conclude that more study is needed to determine the ideal therapeutic approach to treating antihistamine overdoses.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    介绍使用金刚烷胺10年后发生不可逆角膜水肿的情况。进行了文献综述,以描述金刚烷胺引起的角膜水肿的临床特征和结果。
    一名36岁女性,有6周的逐渐进行性双侧无痛性视力丧失的病史,右眼和左眼视力(VA)分别为20/350和20/300,分别。检查显示双侧弥漫性中央角膜水肿伴多处Descemet膜皱褶,无内皮素,角膜沉淀或眼内炎症。这对高渗盐水滴剂和口服阿昔洛韦对假定的疱疹性内皮炎的经验性治疗没有反应。药物审查显示,在过去的10年中,每天使用金刚烷胺100mg,她的神经科医生为疲劳开的处方.尽管停止了金刚烷胺,角膜水肿是不可逆的,因为内皮细胞计数明显降低,分别为625个(右)和680个细胞/mm2(左)。
    该病例强调需要将金刚烷胺视为原因不明的双侧非牙本质角膜水肿的原因。对33例病例报告的文献回顾显示,金刚烷胺诱导的角膜水肿的特征大致相似;而大多数病例具有良好的结局,中位VA20/25(四分位距IQR20/20-20/30),并且在金刚烷胺停药后30天内(IQR14-35)角膜水肿完全消退,最多经历低内皮细胞密度759个细胞/mm2(IQR621-1078)。一起来看,对于可能长期需要金刚烷胺的人,应考虑进行镜面显微镜检查。
    UNASSIGNED: To present a case of irreversible corneal edema after 10 years of amantadine use. A literature review was carried out to describe the clinical characteristics and outcomes of amantadine-induced corneal edema.
    UNASSIGNED: A 36-year-old woman presented with a 6-week history of gradually progressive bilateral painless visual loss with visual acuity (VA) of 20/350 and 20/300 in the right and left eye, respectively. Examination showed bilateral diffuse central corneal edema with multiple Descemet membrane folds without endothelial guttata, keratic precipitates or intraocular inflammation. This did not respond to hypertonic saline drops and empirical treatment for presumed herpetic endotheliitis with oral acyclovir. Medication review revealed the use of amantadine 100mg daily for the past 10 years, prescribed by her neurologist for fatigue. Despite discontinuing amantadine, corneal edema was irreversible due to a markedly reduced endothelial cell count of 625 (right) and 680 cells/mm2 (left).
    UNASSIGNED: This case highlights the need to consider amantadine as a cause of unexplained bilateral non-guttae corneal edema. A literature review of 33 case reports revealed broadly similar features of amantadine-induced corneal edema; whilst most cases had favorable outcomes with median VA 20/25 (interquartile range IQR 20/20-20/30) and complete resolution of corneal edema within 30 days (IQR 14-35) of amantadine discontinuation, most experienced low endothelial cell density 759 cells/mm2 (IQR 621-1078). Taken together, screening specular microscopy ought to be considered for those in whom amantadine is likely required long-term.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    多发性硬化症(MS)是一种慢性神经系统疾病,其特征是中枢神经系统(CNS)的炎症导致神经变性。临床过程变化很大,但是它的患病率在世界范围内上升,部分归功于新的疾病改善疗法。此外,MS患者的寿命在增加,出于这个原因,对MS采用多学科方法是至关重要的。MS可能与心血管疾病(CVD)有关,但是这个问题很少有人关注。特别是,中枢神经系统在调节自主神经系统和心脏活动中是必不可少的。此外,心血管危险因素在MS患者中的患病率较高.另一方面,Takotsubo综合征是MS罕见的并发症。MS和心肌炎之间的平行性也很有趣。最后,心脏毒性代表MS药物并非罕见的不良反应.这篇叙述性综述旨在概述MS的心血管并发症及其管理,以促进对该主题的进一步临床和临床前研究。
    Multiple sclerosis (MS) is a chronic neurological disorder characterized by inflammation in the central nervous system (CNS) that leads to neurodegeneration. The clinical course is highly variable, but its prevalence is rising worldwide, partly thanks to novel disease-modifying therapies. Additionally, the lifespan of people with MS is increasing, and for this reason, it is fundamental to have a multidisciplinary approach to MS. MS may be associated with cardiovascular diseases (CVD), but there is scarce attention on this issue. In particular, CNS is essential in regulating the autonomic system and heart activity. Moreover, cardiovascular risk factors show a higher prevalence in MS patients. On the other hand, conditions like Takotsubo syndrome are rare complications of MS. The parallelism between MS and myocarditis is also interesting. Finally, cardiac toxicity represents a not infrequent adverse reaction to MS drugs. This narrative review aims to provide an overview of cardiovascular complications in MS and their management to prompt further clinical and pre-clinical research on this topic.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    大黄素是大黄的主要药效学成分,具有显著的药理作用和临床疗效。大黄素具有多种治疗作用,比如抗癌,抗纤维化作用,广泛用于治疗脑炎,糖尿病性白内障和器官纤维化。多项研究表明大黄素对器官纤维化有良好的治疗作用,但是机制很复杂。此外,一些研究的证据是相互矛盾和混乱的。本文综述了该机制,大黄素在纤维化治疗中的药代动力学和毒理学,并简要讨论了提高疗效的相关前沿新配方,研究结果可为今后的研究提供一定的参考。
    Emodin is the main pharmacodynamic components of rhubarb, with significant pharmacological effects and clinical efficacy.Emodin has a variety of therapy effects, such as anti-cancer, anti-fibrosis effects, and is widely used to treat encephalitis, diabetic cataract and organ fibrosis. Several studies have shown that emodin has a good treatment effect on organ fibrosis, but the mechanism is complex. Moreover, the evidence of some studies is conflicting and confusing. This paper reviewed the mechanism, pharmacokinetics and toxicology of emodin in fibrosis treatment, and briefly discussed relevant cutting-edge new formulations to improve the efficacy, the result can provide some reference for future study.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Letter
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    通常在实验动物上进行治疗实验以研究毒性剂以及所考虑的药物或物质的可能作用机制。在实验动物模型中使用毒素,包括老鼠,旨在引起毒性。这项研究旨在研究实验动物的肝毒性和肾毒性的不同模型,以帮助研究人员推进他们的研究目标。当前的叙述性审查使用了Medline等数据库,WebofScience,Scopus,和Embase和适当的关键字,直到2021年6月。肾毒性和肝毒性模型来自一些毒性药物,如顺铂,对乙酰氨基酚,阿霉素,一些抗癌药物,和其他材料通过各种信号通路进行了研究。为了了解实验动物的肾或肝毒性模型,在这篇综述中,我们提供了有毒药物及其毒性程序的清单。
    Therapeutic experiments are commonly performed on laboratory animals to investigate the possible mechanism(s) of action of toxic agents as well as drugs or substances under consideration. The use of toxins in laboratory animal models, including rats, is intended to cause toxicity. This study aimed to investigate different models of hepatotoxicity and nephrotoxicity in laboratory animals to help researchers advance their research goals. The current narrative review used databases such as Medline, Web of Science, Scopus, and Embase and appropriate keywords until June 2021. Nephrotoxicity and hepatotoxicity models derived from some toxic agents such as cisplatin, acetaminophen, doxorubicin, some anticancer drugs, and other materials through various signaling pathways are investigated. To understand the models of renal or hepatotoxicity in laboratory animals, we have provided a list of toxic agents and their toxicity procedures in this review.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    用于治疗癌症的新颖且有效的疗法的缺乏是需要优先考虑的紧迫且令人担忧的问题。癌症病例和死亡人数在全球范围内迅速增加。阿霉素,抗癌剂,目前用于治疗几种类型的癌症。它破坏了无数的过程,比如组蛋白驱逐,神经酰胺生产过剩,DNA-加合物形成,活性氧的产生,Ca2+,和铁止血调节。然而,它的使用受到耐药性等因素的限制,毒性,部分患者出现充血性心力衰竭。多柔比星与其他化学治疗剂的组合已被报道为癌症的有效治疗选择,具有很少的副作用。因此,阿霉素和其他化疗药物的杂交被认为是一种有希望的方法,可以产生有效的抗癌药物。这篇综述提供了含有多柔比星及其衍生物支架的杂合化合物的最新研究。
    The scarcity of novel and effective therapeutics for the treatment of cancer is a pressing and alarming issue that needs to be prioritized. The number of cancer cases and deaths are increasing at a rapid rate worldwide. Doxorubicin, an anticancer agent, is currently used to treat several types of cancer. It disrupts myriad processes such as histone eviction, ceramide overproduction, DNA-adduct formation, reactive oxygen species generation, Ca2+, and iron hemostasis regulation. However, its use is limited by factors such as drug resistance, toxicity, and congestive heart failure reported in some patients. The combination of doxorubicin with other chemotherapeutic agents has been reported as an effective treatment option for cancer with few side effects. Thus, the hybridization of doxorubicin and other chemotherapeutic drugs is regarded as a promising approach that can lead to effective anticancer agents. This review gives an update on hybrid compounds containing the scaffolds of doxorubicin and its derivatives with potent chemotherapeutic effects.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    欧洲肝脏研究协会已经为药物引起的肝损伤的研究和管理制定了广泛的指南。这里,我们对这些指南建议产生的一些主要疾病调查和管理进行了评论和概述.
    The European Association for the Study of the Liver has produced extensive guidelines for the investigation and management of drug-induced liver injury. Here, we provide a commentary and overview of some of the principle disease investigations and management that arise from these guideline recommendations.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    未经证实:致幻剂持续知觉障碍(HPPD)影响使用致幻剂的一部分人,被定义为由于先前的中毒而反复出现幻觉和其他知觉障碍。由于正在开发用于治疗选择性疾病的选择性致幻剂,有必要更好地描述这种疾病。
    UNASSIGNED:对HPPD文献的范围审查从开始到2021年7月完成。本文综述涵盖的主题包括HPPD的治疗,不同类别致幻剂中HPPD的患病率或发病率数据,HPPD的危险因素,和有关HPPD病理生理学的数据。
    未经证实:致幻剂持续知觉障碍似乎是与先前致幻剂暴露相关的罕见但严重的事件。人们对迷幻药重新产生了兴趣,将其作为特定精神障碍的潜在治疗选择,尤其是具有致幻潜能的药剂,提供了表征HPPD频率的动力,风险和保护因素,关键特征,以及其他临床和治疗相关因素。
    UNASSIGNED: Hallucinogen persisting perception disorder (HPPD) affects a subset of persons who use hallucinogens and is defined as the repeated experience of hallucinations and other perceptual disturbances as a result of prior intoxications. As select hallucinogens are under development for the treatment of selectmental disorders, there is a need to better characterize this disorder.
    UNASSIGNED: A scoping review of the literature on HPPD was completed from inception to July 2021. Topics covered in the review herein include treatments for HPPD, prevalence or incidence data on HPPD among different classes of hallucinogens, risk factors for HPPD, and data pertaining to the pathophysiology of HPPD.
    UNASSIGNED: Hallucinogen persisting perception disorder appears to be an uncommon yet serious event associated with prior hallucinogen exposure. The renewed interest in psychedelics as potential treatment options for select mental disorders, especially agents with hallucinogenic potential, provides the impetus to characterize HPPD in its frequency, risk and protective factors, key characteristics, as well as other clinical and treatment-related factors.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号